Christian Caglevic
0000-0003-3319-1678
Publication & Citation Trends
Publications
0 total
Vibostolimab coformulated with pembrolizumab versus pembrolizumab alone as adjuvant therapy for high-risk stage IIB-IV melanoma (KEYVIBE-010): a randomised, double-blind, phase 3 study.
Cited by 0
Semantic Scholar
Adjuvant pembrolizumab plus belzutifan versus pembrolizumab for clear cell renal cell carcinoma (ccRCC): The randomized phase 3 LITESPARK-022 study.
Cited by 0
Semantic Scholar
KEYMAKER-U04 substudy 04B: First-line (1L) enfortumab vedotin (EV) plus pembrolizumab (pembro)-based immune checkpoint inhibitor (ICI) combinations for advanced urothelial cancer (UC).
Cited by 0
Semantic Scholar
3145P A phase II study of participant (pt)-reported preference for pembrolizumab (pembro) administered subcutaneously (SC) or intravenously (IV)
Cited by 0
Semantic Scholar
Abstract CT035: Pharmacokinetics (PK), safety, and tolerability of pembrolizumab with berahyaluronidase alfa administered subcutaneously Q3W in participants with advanced melanoma
Cited by 0
Semantic Scholar
The KRAS G12C inhibitor MK-1084 for KRAS G12C–mutated advanced colorectal cancer (CRC): Results from KANDLELIT-001.
Cited by 6
Semantic Scholar
Vibostolimab coformulated with pembrolizumab (vibo/pembro) for previously treated advanced mismatch repair–deficient (dMMR) endometrial cancer: Results from cohort B1 of the phase 2 KEYVIBE-005 study.
Cited by 5
Semantic Scholar
Epacadostat Plus Pembrolizumab versus Placebo Plus Pembrolizumab in Patients with Unresectable or Metastatic Melanoma: Results of the Phase 3, Randomised, Double-Blind Echo-301/Keynote-252 Study
Cited by 2
Semantic Scholar
Research Topics
Cancer Immunotherapy and Biomarkers
(37)
Lung Cancer Treatments and Mutations
(21)
Gastric Cancer Management and Outcomes
(19)
Colorectal Cancer Treatments and Studies
(11)
Pancreatic and Hepatic Oncology Research
(10)
Affiliations
Universidad del Desarrollo
Clínica Alemana
Hôpital René Huguenin
Centrum Onkologii
Fundación Arturo López Pérez